ECTF- Important this month

Introduction

This page is for EC Trial Finder coordinators and data managers. Here you can find key updates related to your monthly EC Trial Finder information submission.

Below you can find

1) Notice on what is important for this month’s trial submission
2) Information about the Sponsor notification process and current blanket approvals
3) List of trials that were removed or edited by the Programme Office this month

 
 

Important for data submission this month:
(last updated 01/06/2023)

  • Include any new trials and changes to trials since October.. Please add these updates to the database.
  • Check the cancer types listed for each of your trials. In the new platform you’re able to include the specific cancer types/cohorts that are open at your Site. In the old ECTF set up the cancer types/cohorts had to be identical across all sites for the multi-site trials. Please review all your trials and either add new cohorts if you see any missing or remove your Site from any that are not open at your Site, so the information is accurate for your site.
  • Review the molecular marker eligibility criteria and see if more detailed information can be added for each of the markers. You can now provide more detailed and structured information for each molecular marker listed as part of the eligibility criteria. For example, you can specify if it is a ‘mutation’, ‘amplification’ ‘positive’, etc. You can do this by reporting it to us and we will make the changes for you after your submission. Please use the ‘report change/incorrect information’ link on the platform to do this. For any new trials/cohorts you add you can add this detail yourself
  • Review whether the molecular marker eligibility criteria is relevant for each cancer cohort within a trial or only to some/one of them. We are now able to collect the molecular marker eligibility criteria for each cancer type/cohort within a trial. Previously this was done at trial level and the same eligibility was applied to all cancer types that were part of the trial. Sometimes the molecular marker eligibility (e.g. HER2 positive) might not be relevant for all cohorts of a trial (e.g., only for breast cancer but not colon). In the new platform you can provide this information separately for each cohort, so it is more accurate. Please review whether any changes are needed and if certain markers should be removed from the cancer cohorts in multi-cohort trials.  Again, use the “report change/incorrect details” link in the platform to report any changes that are needed.
  • Review the ‘additional eligibility criteria’ for each trial to see if more values need to be added. Previously you were only able to add one criteria from the excel dropdown list. Some trials might have several eligibility criteria that might be relevant from the provided list. Please review whether any changes are needed and report those to us as above so we can update these for you.

 

Sponsor notification process & current blanket approvals

EC Trial Finder has the following Sponsor notification process in place -

  • You/one of the other sites provide us the Sponsor’s name and address in the data entry platform
  • CRUK will write to the Sponsor to notify them that the trial that they sponsor has been published on ECTF

The current process is done primarily as courtesy as the information is publicly available

All sponsors have had a positive response as the tool benefits their trial recruitment and several have asked to sign ''Sponsor blanket approval' which means they no longer need to be notified.

The below Sponsors have  blanket approval in place so  you do not need to provide address details -

  • Amgen
  • AstraZeneca
  • Bayer AG
  • Cancer Research UK CDD
  • f.Hoffman - La Roche
  • GlaxoSmithKline UK Ltd (GSK)
  • Janssen
  • Nurix Therapeutics Inc.
  • Pyramid Biosciences
  • Scancell
  • Servier Research & Development Ltd

 

Trials that have been removed or edited by the PO this month 

Trials that we have removed 

Trials that we have made changes to

Please do not hesistate to contact us if you need clarification or have any questions on ECTrialFinder@cancer.org.uk